OTCMKTS:JCRRF JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis $4.57 0.00 (0.00%) As of 05/7/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get JCR Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.57▼$4.5750-Day Range$4.57▼$4.5752-Week Range$4.30▼$4.70VolumeN/AAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.Read More… Receive JCRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JCRRF Stock News HeadlinesJCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual MeetingMay 8 at 12:05 PM | businesswire.comNotice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDAMay 7 at 7:11 PM | uk.finance.yahoo.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. May 8, 2025 | Timothy Sykes (Ad)JCR Pharmaceuticals Nominates New Audit & Supervisory Board MembersApril 25, 2025 | tipranks.comJCR Pharmaceuticals Begins Construction of New Drug Product PlantFebruary 25, 2025 | tipranks.comJCR Pharmaceuticals' Research Presentations at WORLDSymposiumâ„¢ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage DisordersFebruary 5, 2025 | businesswire.comJCR Pharmaceuticals Showcases Promising Data at WORLDSymposium™ 2025February 5, 2025 | tipranks.comJCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from JefferiesJanuary 29, 2025 | markets.businessinsider.comSee More Headlines JCRRF Stock Analysis - Frequently Asked Questions How have JCRRF shares performed this year? JCR Pharmaceuticals' stock was trading at $4.57 at the beginning of 2025. Since then, JCRRF stock has increased by 0.0% and is now trading at $4.57. View the best growth stocks for 2025 here. How do I buy shares of JCR Pharmaceuticals? Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/08/2025Next Earnings (Estimated)5/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:JCRRF CIKN/A Webwww.jcrpharm.co.jp Phone81 7 9732 8591FaxN/AEmployees934Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:JCRRF) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersIt may already be too late… A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage a...Huge Alerts | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredBitcoin Just Broke $100K – Are You Positioned?This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.